Next Article in Journal
Nutrition, Obesity and Asthma Inception in Children. The Role of Lung Function
Next Article in Special Issue
Association between Self-Reported Gluten Avoidance and Irritable Bowel Syndrome: Findings of the NutriNet-Santé Study
Previous Article in Journal
Nutraceuticals and Cancer: Potential for Natural Polyphenols
Article

The Effects of Human Milk Oligosaccharides on Gut Microbiota, Metabolite Profiles and Host Mucosal Response in Patients with Irritable Bowel Syndrome

1
Department of Microbiology and Immunology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, 40530 Gothenburg, Sweden
2
Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, 40530 Gothenburg, Sweden
3
DSM, Kogle Alle 4, 2970 Hørsholm, Denmark
4
Department of Technology, Faculty of Health, University College Copenhagen, 1799 Copenhagen, Denmark
5
Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield S10 2JF, UK
6
Quadram Institute Bioscience, Norwich Research Park, Norwich NR4 7UQ, UK
7
MS-Omics, 2950 Copenhagen, Denmark
8
Clinical Microbiomics, 2100 Copenhagen, Denmark
9
Center for Functional GI and Motility Disorders, University of North Carolina, Chapel Hill, NC 27599, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Jean-Marc Sabaté
Nutrients 2021, 13(11), 3836; https://doi.org/10.3390/nu13113836
Received: 23 September 2021 / Revised: 22 October 2021 / Accepted: 25 October 2021 / Published: 27 October 2021
Background: Human milk oligosaccharide supplementation safely modulates fecal bifidobacteria abundance and holds the potential to manage symptoms in irritable bowel syndrome (IBS). Here, we aimed to determine the role of a 4:1 mix of 2′-O-fucosyllactose and lacto-N-neotetraose (2′FL/LNnT) on the modulation of the gut microbiota composition and host mucosal response, as well as the link between the bifidobacteria abundance and metabolite modulation, in IBS patients. Methods: Biological samples were collected from IBS patients (n = 58) at baseline and week 4 post-supplementation with placebo, 5 g or 10 g doses of 2′FL/LNnT. The gut microbiota composition, metabolite profiles and expression of genes related to host mucosal response were determined. Results: Moderate changes in fecal, but not mucosal, microbial composition (β-diversity) was observed during the intervention with higher dissimilarity observed within individuals receiving 10g 2′FL/LNnT compared to placebo. Both fecal and mucosal Bifidobacterium spp. increased after 2′FL/LNnT intake, with increased proportions of Bifidobacterium adolescentis and Bifidobacterium longum. Moreover, the intervention modulated the fecal and plasma metabolite profiles, but not the urine metabolite profile or the host mucosal response. Changes in the metabolite profiles were associated to changes in bifidobacteria abundance. Conclusion: Supplementation with 2′FL/LNnT modulated the gut microbiota, fecal and plasma metabolite profiles, but not the host mucosal response in IBS. Furthermore, the bifidogenic effect was associated with metabolite modulation. Overall, these findings support the assertion that 2′FL/LNnT supplementation modulate the intestinal microenvironment of patients with IBS, potentially related to health. View Full-Text
Keywords: 2′-O-fucosyllactose; antibacterial response; gut microenvironment; human milk oligosaccharides; irritable bowel syndrome; lacto-N-neotetraose; metabolomics; microbiota 2′-O-fucosyllactose; antibacterial response; gut microenvironment; human milk oligosaccharides; irritable bowel syndrome; lacto-N-neotetraose; metabolomics; microbiota
Show Figures

Graphical abstract

MDPI and ACS Style

Iribarren, C.; Magnusson, M.K.; Vigsnæs, L.K.; Aziz, I.; Amundsen, I.D.; Šuligoj, T.; Juge, N.; Patel, P.; Sapnara, M.; Johnsen, L.; Sørensen, N.; Sundin, J.; Törnblom, H.; Simrén, M.; Öhman, L. The Effects of Human Milk Oligosaccharides on Gut Microbiota, Metabolite Profiles and Host Mucosal Response in Patients with Irritable Bowel Syndrome. Nutrients 2021, 13, 3836. https://doi.org/10.3390/nu13113836

AMA Style

Iribarren C, Magnusson MK, Vigsnæs LK, Aziz I, Amundsen ID, Šuligoj T, Juge N, Patel P, Sapnara M, Johnsen L, Sørensen N, Sundin J, Törnblom H, Simrén M, Öhman L. The Effects of Human Milk Oligosaccharides on Gut Microbiota, Metabolite Profiles and Host Mucosal Response in Patients with Irritable Bowel Syndrome. Nutrients. 2021; 13(11):3836. https://doi.org/10.3390/nu13113836

Chicago/Turabian Style

Iribarren, Cristina, Maria K. Magnusson, Louise K. Vigsnæs, Imran Aziz, Ingvild D. Amundsen, Tanja Šuligoj, Nathalie Juge, Piyush Patel, Maria Sapnara, Lea Johnsen, Nikolaj Sørensen, Johanna Sundin, Hans Törnblom, Magnus Simrén, and Lena Öhman. 2021. "The Effects of Human Milk Oligosaccharides on Gut Microbiota, Metabolite Profiles and Host Mucosal Response in Patients with Irritable Bowel Syndrome" Nutrients 13, no. 11: 3836. https://doi.org/10.3390/nu13113836

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop